The advent of immunotherapy has resulted in significant survival benefits in cancer care. The immune response is however heterogeneous across tumors and individuals, rendering existing therapeutics non-effective for many patients. My research focuses on identification of biomarker signatures for patient stratification and new treatment strategies through comprehensive characterization of the tumor immune microenvironment.